Showing studies matching your search14 results shown

Studies (14 shown)

NCT06324357PHASE1, PHASE2RECRUITING

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Sponsor · Boehringer IngelheimCondition · Metastatic Breast Cancer, Metastatic Gastric AdenocarcinomaIntervention · Zongertinib, Trastuzumab deruxtecanUpdated May 2026
NCT07486817PHASE2NOT_YET_RECRUITING

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

Sponsor · Boehringer IngelheimCondition · Lung Cancer, Non-squamous, Non-small CellIntervention · Zongertinib, CisplatinUpdated May 2026
NCT06151574PHASE3ACTIVE_NOT_RECRUITING

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Sponsor · Boehringer IngelheimCondition · Lung Cancer, Non-squamous, Non-small CellIntervention · zongertinib, pembrolizumabUpdated May 2026
NCT04886804PHASE1ACTIVE_NOT_RECRUITING

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Sponsor · Boehringer IngelheimCondition · Neoplasm Metastasis, Non-Small Cell Lung CancerIntervention · zongertinibUpdated May 2026
NCT07195695PHASE3RECRUITING

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Sponsor · Boehringer IngelheimCondition · Non-small Cell Lung CancerIntervention · Zongertinib, PembrolizumabUpdated May 2026
NCT06581432PHASE2RECRUITING

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Sponsor · Boehringer IngelheimCondition · Solid TumoursIntervention · ZongertinibUpdated Apr 2026
NCT06504862PHASE1COMPLETED

A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood

Sponsor · Boehringer IngelheimCondition · HealthyIntervention · Zongertinib, Dabigatran-etexilateUpdated Jan 2026
NCT06028464PHASE1COMPLETED

A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Zongertinib in the Blood

Sponsor · Boehringer IngelheimCondition · HealthyIntervention · Zongertinib, CarbamazepineUpdated Nov 2025
NCT05879991PHASE1COMPLETED

A Study in Healthy Men to Test How Zongertinib (BI 1810631) is Taken up and Processed by the Body

Sponsor · Boehringer IngelheimCondition · HealthyIntervention · zongertinib (C-14), zongertinibUpdated Oct 2025
NCT05833139PHASE1COMPLETED

A Study in Healthy Men to Test How Itraconazole Influences the Amount of Zongertinib (BI 1810631) in the Blood

Sponsor · Boehringer IngelheimCondition · HealthyIntervention · Zongertinib, ItraconazoleUpdated Sep 2025
NCT06360081PHASE1COMPLETED

A Study in Healthy People to See How Zongertinib is Taken up Into the Blood When Given as Tablets Made by Two Different Manufacturers

Sponsor · Boehringer IngelheimCondition · HealthyIntervention · Zongertinib manufacturer 1, Zongertinib manufacturer 2Updated Sep 2025
NCT06075277PHASE1COMPLETED

A Study in Healthy Men to Test How Zongertinib is Taken up in the Body When Taken With or Without Food

Sponsor · Boehringer IngelheimCondition · HealthyIntervention · zongertinibUpdated Sep 2025
NCT06692322PHASE1COMPLETED

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

Sponsor · Boehringer IngelheimCondition · Liver Diseases, HealthyIntervention · Zongertinib (BI 1810631)Updated Aug 2025
NCT05380947PHASE1COMPLETED

A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood

Sponsor · Boehringer IngelheimCondition · HealthyIntervention · BI 1810631 - trial formulation 1 (TF1), BI 1810631 - new formulation (NF)Updated Nov 2025
Showing top 14 results. See all 14 results on CT.gov →